Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 10/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.42 |
| ▸ | PRKDC | P78527 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9884189 | 0.89 | PIK3CG (0.52) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL9884151 | 0.88 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL29479405 | 0.88 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL954241 | 0.88 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL29479398 | 0.87 | PIK3CD (0.68) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL958791 | 0.87 | PIK3CD (0.68) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL9884172 | 0.86 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL9884125 | 0.86 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL9899453 | 0.86 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL9884152 | 0.86 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11433065-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2022-09-06 | — | — | US | disclosed |
| EP-3613743-B1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | INTELLIKINE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3811974-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| EP-2240452-B1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES AS PI3 KINASE MODULATORS, THEIR COMPOSITIONS AND USES | INTELLIKINE LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PIK3CG 2/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PIK3CG 2/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PIK3CG 2/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CG 8/4885PIK3CD 7/4885PIK3CA 1/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CG 15/4885PIK3CD 6/4885PIK3CA 1/4885 |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIK3CG 8/4885PIK3CD 7/4885PIK3CA 1/4885 |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PIK3CG 9/4885PIK3CD 5/4885PIK3CA 1/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PIK3CG 6/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-11433065-B2 | Certain chemical entities, compositions and methods | PIK3CA, AKT3, PIK3C2A | PIK3CG 8/4885PIK3CD 7/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.